Article Excerpt: An Israeli pharmaceutical company will begin late-stage testing on a non-opiate pain relief with the hope that the technology can easily be adapted into the U.S. market after receiving support from the Food and Drug Administration. Israeli firm PainReform received FDA approval to start a phase-III clinical trial of an extended-release pain reliever, called PRF-110. The drug is meant to be used for post-surgical incision pain and has been shown to last up to 72 hours — 10 times longer than the current standard of care, the company said in a statement.
Full Article: https://tinyurl.com/y7am8f6f
Article Source: The Washington Times